Health ❯Healthcare ❯Research Studies

Clinical Research

Hormones Diabetes Obesity Clinical Studies Adverse Effects Clinical Trials Chronic Diseases Research Studies Pharmaceuticals Patient Care

Novo Nordisk’s Amycretin Achieves Up to 24% Weight Loss as It Advances to Phase 3

The phase 1 data reveal sustained weight reduction with tolerable gastrointestinal effects ahead of planned 2026 phase 3 trials.

Biannual Zilebesiran Injections Significantly Lower Blood Pressure in Resistant Hypertension